Rosetta Genomics Receives Notice of Allowance for U.S.

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Rosetta Genomics Receives Notice of Allowance for U.S. Patent for the Treatment of Ovarian Cancer

PRINCETON, NJ and REHOVOT, ISRAEL--(Marketwired - Jul 10, 2014) -  Rosetta Genomics Ltd. ( NASDAQ : ROSG ), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, announces receipt of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application No. 13/977,797, entitled "Compositions and Methods for Treatment of Ovarian Cancer." The patent relates to inhibition of miR-210 for the treatment of ovarian cancer.

Treatment for advanced ovarian carcinoma is typically based on the combination of surgery and chemotherapy. The objective of surgical intervention in patients suffering from advanced disease is to perform cyto-reduction to minimal residual disease in the abdominal cavity. Surgery is followed by adjuvant platinum based chemotherapy. Although 80-90% of patients initially respond to first line treatment, most will either progress during therapy or recur after complete remission. Ovarian cancer causes more deaths than any other gynecologic cancer.

"This new patent allowance complements and extends the broad intellectual property protection we have established for oncology therapeutics and represents a valuable addition to our microRNA patent estate," stated Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics. "Ovarian cancer remains a serious unmet medical need where there is a great demand for effective new therapies. microRNAs represent potential targets for the development of novel drugs and our growing patent portfolio for oncology therapeutics represents a valuable asset for development and/or monetization. Rosetta is a pioneer of microRNA technology and our broad and expanding patent portfolio will continue to protect and maintain our leadership position, as the vast potential of microRNA technologies is becoming realized."

"Rosetta has previously shown that microRNA-based diagnostics can provide significant insights into predicting response to platinum-based therapeutic regimens, which are the first line treatment for ovarian cancer. This capability is of greater value today as new agents are emerging with efficacy in ovarian cancer that provide potential alternatives when platinum is determined to be of unlikely benefit and may, therefore, be added to our clinical diagnostic portfolio going forward to leverage investments in our commercial and laboratory infrastructure," added Dr. E. Robert Wassman, Chief Medical Officer of Rosetta Genomics.

Rosetta's robust patent portfolio includes 36 issued patents, including 32 in the U.S. In addition, Rosetta has 49 patent applications pending, of which 27 are in the U.S.

About Ovarian Cancer According to the National Cancer Institute, nearly 22,000 women in the United States will be diagnosed with ovarian cancer and over 14,000 women will die from ovarian cancer in 2014. Ovarian cancer is the eighth most common cancer and the fifth leading cause of cancer death among women in the U.S. Ovarian cancer causes more deaths than any other gynecologic cancer, but it accounts for only about 3 percent of all cancers in women.

In spite of considerable research into therapies for ovarian cancer, ovarian cancer remains difficult to diagnose and treat effectively, and the mortality observed in patients indicates that improvements are needed in the treatment and prevention of the disease.

About Rosetta Genomics Founded in 2000, Rosetta's integrative research platform combining bioinformatics and state-of- the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools and therapeutics. Rosetta currently commercializes a full range of microRNA-based molecular diagnostics. Rosetta's cancer testing services are commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab. For more information please visit www.rosettagenomics.com .

Forward-Looking Statement Disclaimer Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, Rosetta's Cancer of Origin Test™, Rosetta's development or commercialization of molecular diagnostics, prognostic or therapeutic services or tools, Rosetta's monetizing its intellectual property estate in any way and Rosetta's development of personalized medicine products and services, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2012 as filed with the SEC. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

Rosetta Genomics Contact: Rosetta Genomics Ken Berlin President & CEO 609-419-9003 investors@rosettagenomics.com Investor Contacts: LHA Anne Marie Fields 212-838-3777 afields@lhai.com or Bruce Voss 310-691-7100 bvoss@lhai.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Carbonization Furnaces Turn Waste Rules Into Demand

Updated Category News Views 84

Smoke has become an expensive habit for farmers, mills, and municipalities. That is the real commercial backdrop for carbonization furnaces, not some glossy green-tech slogan. MarketsandMarkets estimates this small global equipment market at $310 million in 2026 and projects $510 million by 2031, a 10.2% compound annual growth rate. For a capital-equipment niche, that is...

Continue Reading
BreakBio's New CSO Adds Vaccine Trial Credibility in Cancer

Updated Category News Views 104

Personalized cancer vaccines have no shortage of grand promises; seasoned clinical operators are the rarer commodity. That is why BreakBio's appointment of Dr. Greg Lizée as chief scientific officer deserves a closer look, even if nobody should confuse an executive hire with clinical validation. BreakBio is private, its lead program remains in development, and cancer...

Continue Reading
Mindstream’s Jordan AI Campus Faces Its First Real Test

Updated Category News Views 31

Jordan’s AI ambitions just got attached to a very large gas meter. Mindstream Energy has unveiled a plan for an AI-ready data-center campus at Al-Risha in Mafraq Governorate, built around dedicated natural-gas generation rather than a conventional dependence on the utility grid. The headline number is 400 megawatts of eventual capacity. The number that matters first is...

Continue Reading
ACOLT Bets on Gold, Craft, and a Sci-Fi Story World

Updated Category News Views 74

A gold pendant moonlighting as a plot device is not the usual luxury pitch, and thank goodness for that. ACOLT, the Denver-based men's fine jewelry house founded by Colton Hindle, plans an international December 2026 launch of its Gold Collection alongside CHRYSON Volume 1: The Arrival, an original science-fiction comic. The actual hand-forged pieces are meant to show up...

Continue Reading
Receipts Turns Vegas Party Shirts Into AR Keepsakes

Updated Category News Views 123

A shirt that coughs up a Vegas weekend when scanned is either a smart little keepsake trick or a privacy headache wearing sequins. Receipts™, introduced by Las Vegas-based Naked City Couture and the AR Trading Card Company, is betting it can be the former. The concept is simple enough: friends wear the apparel, capture photos and videos during a trip, upload those...

Continue Reading
Software-Defined Cars Put $310 Billion in Play by 2035

Updated Category News Views 71

Cars are becoming rolling computers, and that changes who gets paid. Market Growth Reports projects the software-defined vehicle market will rise from $56.94 billion to $310.46 billion by 2035, a 20.74% compound annual growth rate. That is a loud number, no question. Still, investors ought to treat any long-range market forecast like a map, not a mortgage deed. The...

Continue Reading
Stanford Forum Puts Industrial AI in the Real World

Updated Category News Views 144

Factory Data Is Not a Free Lunch A factory dataset is worth precisely nothing if its owner cannot control it. That was the hard-nosed thread running through the ASI City Forum at Stanford on November 17: industrial AI is not just about smarter models or splashy chip announcements. It is about whether manufacturers will trust a system with proprietary operating data,...

Continue Reading
Hyster-Yale’s $135 Million Convert Carries Real Cost

Updated Category News Views 143

Forklift makers do not usually get to hide a 7.50% borrowing cost behind glossy financing jargon. Hyster-Yale has priced $135 million of convertible senior notes due in 2031, lifting the deal from the originally announced $125 million. There is also an option for initial purchasers to take another $20 million. For NYSE:HY shareholders, this is not a simple debt cleanup....

Continue Reading
Tigerlily Takes Its Advocacy Model to Ovarian Cancer

Updated Category News Views 166

Ovarian cancer has a nasty habit of hiding behind symptoms people are taught to shrug off. Persistent bloating or pelvic pain can look like any number of ordinary problems, and that ambiguity is exactly why practical, trusted education matters. Tigerlily Foundation's new ovarian cancer initiative is not a flashy breakthrough claim. It is a grounded attempt to help women...

Continue Reading
Makera A1S Tests the Desktop CNC Metal-Cutting Promise

Updated Category News Views 61

Aluminum chips are where desktop-machine marketing stops bluffing, and Makera is leaning right into that test with the A1S. The company opened global pre-orders on November 18 for a machine aimed squarely at the awkward middle ground: users who have outgrown entry-level hobby gear but do not have room, budget, or patience for a full industrial setup. That is a real market...

Continue Reading

Top 5 Most Recently Viewed Articles

Future Growth of the Premium Chocolate Sector: Insights and Trends

Updated Category News Views 85

An Insight into the Premium Chocolate Market The global premium chocolate market is experiencing remarkable growth, with projections indicating an increase of USD 20.8 billion between 2024 and 2028. This growth is expected to occur at a compound annual growth rate (CAGR) of 9.48%. Key drivers for this rise encompass new product launches and evolving consumer preferences....

Continue Reading
Lovesac's Commitment to Sustainability: The 2024 ESG Report

Updated Category News Views 260

Understanding Lovesac's 2024 ESG Report The Lovesac Company (NASDAQ: LOVE) has recently published its Environmental, Social, and Governance (ESG) Report for the fiscal year ending February 4, 2024. This comprehensive report showcases the company’s unwavering commitment to sustainability and responsible business practices, emphasizing their innovative product offerings...

Continue Reading
How High-Net-Worth Investors Can Save Millions in Taxes

Updated Category News Views 171

Strategies for High-Net-Worth Investors to Manage Tax Implications In a world where technology and artificial intelligence are reshaping the investment landscape, the CEO of Wealthstone, Zak Gardezy, offers new insights for high-net-worth individuals. His recent publication, Secrets of a Wealth Advisor: How To Diversify Concentrated Stock Tax Efficiently, focuses on...

Continue Reading
Major Leadership Change at Camping World Holdings Inc. Revealed

Updated Category News Views 251

Marcus Lemonis Steps Down from Camping World Holdings Inc. Marcus Lemonis, a prominent entrepreneur and television personality famed for his roles in popular shows, has announced his departure as CEO of Camping World Holdings Inc. (NYSE: CWH). This announcement marks a significant change for the company Lemonis co-founded, which has grown into a leading name in the...

Continue Reading
Market Outlook Update: Novozymes' Stock Rating Downgrade

Updated Category News Views 131

Recent Downgrade of Novozymes Stock by Citi Novozymes A/S (OTC: NVZMY) recently faced a significant shift in its market perception as Citi has downgraded the company’s stock rating from Neutral to Sell. Even with this downgrade, the price target has seen a slight improvement—from DKK390.00 to DKK400.00. This change arrives despite the company showcasing a remarkable...

Continue Reading